199.57MMarket Cap-10597P/E (TTM)
7.190High6.098Low110.54KVolume6.310Open6.300Pre Close724.70KTurnover11.05%Turnover RatioLossP/E (Static)29.61MShares20.72052wk High66.08P/B6.74MFloat Cap4.76052wk Low--Dividend TTM1.00MShs Float20.720Historical High--Div YieldTTM17.33%Amplitude4.760Historical Low6.555Avg Price1Lot Size
Telomir Pharmaceuticals Stock Forum
NEWS
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals presents promising pre-clinical data on Telomir-1 at a National Press Club event, showcasing a 40% increase in telomerase activity and lengthening of telomeres in human cells. The company plans to initiate human clinical trials for osteoarthritis and veterinary trials in 2025 after pre-clinical...
No comment yet